Severe 5 -fluorouracil ( 5 -FU ) toxicity has been reported among patients lacking dihydropyrimidine dehydrogenase ( DPD ) enzymatic activity. DPD is the principal enzyme involved in the degradation of 5 -FU to 5 0 -6 0 -dihydrofluorouracil, which is further metabolized to fluoro --alanine. We demonstrate here that overexpression of human DPD confers resistance to 5 -FU in 
B one marrow suppression is the dose -limiting toxicity for most currently available chemotherapy agents. This toxicity often causes treatment delay or dose modification, which may compromise antitumor effects. Growth factor support and autologous stem cell transplantation have allowed a modest increase in dose intensity of anticancer agents. 1 -5 Transfer of drug resistance genes into hematopoietic progenitor cells is a promising approach to reduce drug -induced myelosuppression and may also allow for dose intensification especially after bone marrow or stem cell transplant. Interestingly, transfer of a mutant dihydrofolate reductase gene into hematopoietic precursors protected not only bone marrow cells, but also reduced gastrointestinal toxicity in the mouse. 6, 7 Dihydropyrimidine dehydrogenase (DPD ) is the initial rate -limiting enzyme in pyrimidine catabolism and has an important role in the catabolism of 5 -fluorouracil ( 5-FU ), which is often used as an anticancer drug. 8 -11 The antitumor effect and toxicity of 5 -FU are directly related to anabolism of 5 -FU to its nucleotides that cause inhibition of thymidylate synthase activity or incorporation into RNA or DNA. The role of catabolism in 5 -FU toxicity or therapeutic response, however, has not been understood until recently. In humans, more than 85% of administered 5-FU is catabolized by DPD. 9, 11 The enzyme DPD is present in most tissues, including liver, fibroblasts, and peripheral blood mononuclear cells. 12 -14 The cDNA for this gene was cloned and sequenced by Yokota et al. 15 DPD -deficient cancer patients treated with 5 -FU present with severe 5-FU toxicity, even leading to death. 16 -18 DPD inhibitor studies have also shown the importance of DPD in 5 -FU metabolism, as doses of 5 -FU have to be decreased markedly because of toxicity.
It is not yet clear if antitumor toxicity is enhanced by this approach. 19 -22 Hematopoietic progenitor cells may be protected from 5 -FU toxicity by increased activity of this catabolic enzyme. 5 -FU is not known to be myeloablative, but may cause severe myelosuppression especially with repetitive administration of the drug. 23, 24 The studies reported in this paper demonstrate the potential myeloprotective value of gene transfer and expression of DPD in hematopoietic progenitor cells. Successful transduction of hematopoietic precursors in patients with DPD cDNA may allow administration of larger doses and or more frequent administration of 5 -FU, and may lead to improved outcomes.
MATERIALS AND METHODS

Cells
NIH3T3 cells were cultured in Dulbecco's modified Eagle high -glucose (with 4.5 g /L glucose ) (DME -HG ) media with 10% fetal bovine serum ( FBS ). The viral packaging cell line GP -envAM12, an amphotropic line, and GPenvE86, an ecotropic line, have been described. 25, 26 
Retrovirus constructs
The human DPD cDNA in pUC9 ( provided by Dr. Frank J. Gonzalez, Laboratory of Molecular Carcinogenesis, National Cancer Institute, Bethesda, MD ) was digested with Hindlll and EcoRI for subcloning into a pCDNA3 vector ( Invitrogen, Carlsbad, CA ). DPD cDNA was digested at BspHI sites (both at 570 bp downstream of the DPD stop codon and at the multiple cloning site in pCDNA3 vector ), filled in with Klenow enzyme ( New England Biolabs, Bevery, MA ), ligated with XhoI linker (New England Biolabs), and digested with NcoI and XhoI to obtain DPD cDNA with the fragment containing 5 0 NcoI and 3 0 XhoI sites. This fragment was subcloned into an SFG -based vector ( vector provided by Dr. Michel Sadelain, Department of Human Genetics, Memorial Sloan -Kettering Cancer Center, New York, NY ) backbone to create SFG -DPD. The SFG vector contains a Moloney murine leukemia virus ( MMLV ) -derived 5 0 -LTR and a chimeric 3 0 -LTR that contains the myeloproliferative sarcoma virus (MPSV ) promoter / enhancer. 27 After digestion with BglII and XhoI, this fragment was subcloned into a SFG -NTP -IRES -Neo ( NTP: mutated nerve growth factor receptor gene ) vector ( provided by Dr. Michel Sadelain ), digested with BglII and XhoI, to obtain SFG -DPD -IRES -Neo, replacing NTP by DPD. The presence of a full -length DPD cDNA was confirmed by restriction enzyme digestion. Figure 1 shows this construct.
Retrovirus producer cell lines
The retrovirus vector construct, SFG -DPD -IRES -Neo, was transfected into GP -AM12 and GP -E86 packaging cells using a DOTAP reagent ( Boehringer-Mannheim, Indianapolis, IL ). After a 14 -day selection with 750 g/mL G418, colonies with high titers were selected. Titers of these producer cell lines were measured using NIH3T3 cells as a target, and the highest titer colonies were used for further experiments. The titer of these colonies was 1-5Â10 6 cfu /mL. The producer cells were replated in 100 -mm plates and grown to 80% confluency. The growth medium was changed to 10 mL of fresh media, either DME -HG with 10% FBS for 3T3 cell infection, or Iscove's modified Dulbecco's medium (IMDM) containing 10% FBS for bone marrow infection. The next day, the supernatant was collected and centrifuged at 1300Âg for 20 minutes to remove cell debris. The viral supernatant stock was stored at À 708C until use. The producer cell lines AM12-SFG -DPD -IRES -Neo and E86 -SFG -DPD -IRES -Neo were free of replicationcompetent retrovirus as demonstrated by the failure of G418 resistance to be transferred from virally transduced NIH3T3 cells to nontransduced NIH3T3 cells, as described by Persons et al. 28 In brief, 10 mL of supernatant from producer cells was used to transduce 1Â10 5 NIH3T3 cells, which were passaged for 3 weeks without selection. Ten milliliters of conditioning media from these cells was then used to transduce 1Â10 5 nontransduced NIH3T3 cells, and 48 hours later, selection was applied with 750 g /mL G418 in DME HG with 10% FBS. No G418 -resistant colonies were observed.
Protection of NIH3T3 cells from 5 -FU toxicity after transfection with retroviral vectors containing human DPD cDNA. NIH3T3 cells were exposed to supernatant containing the retroviral construct at an MOI of 5, in the presence of 8 g/mL polybrene. After 6 hours, fresh medium was added to dilute the supernatant, then at 24 hours, medium was changed to DME -HG containing 750 g/ mL G418 for 10 -day selection. After the 10-day selection, cells were plated in 96 -well plates, and cytotoxicity was determined spectrophotometrically by the XTT assay (sodium 3 0 -[1-{(phenylamino)-carbonyl)-3,4-tetrazolium]-bis( 4 -methoxy -6 -nitro ) benzene -sulfonic acid hydrate ), as described previously. 29 Cells were plated at a density of 400 cells/well, and 24 hours later, exposed to drugs. After 5 days of exposure to drugs, 50 L of XTT at a concentration of 1 mg /mL was added together with phenazine methosulfate ( PMS). After a 3 -hour incubation at 378C, the OD at 450 nm was measured using a 96 -well plate reader. The cell survival data were plotted TAKEBE, ZHAO, URAL, ET AL: DPD GENE TRANSFER AND 5-FU RESISTANCE using wells without drug ( with cells ) as 100% and wells containing media without cells as 0%.
Polymerase chain reaction ( PCR ) analysis of genomic DNA from NIH3T3 cells. Genomic DNA from NIH3T3 cells was isolated as described previously 30 and 200 ng was used for each PCR reaction. For detection of human DPD cDNA, forward DPD1 (5 0 -ATGGCCCCTGTGCTCAGTAAGGA-C-3 0 ) and reverse DPD2 ( 5 0 -AGCACAACTTAT ACTTG-CAGGCCC -3 0 ) primers designed to amplify a 610-bp sequence encoding a 5 0 human DPD cDNA sequence were used.
Toxicity of 5 -FU to cells infected with retroviral vectors containing human DPD with coadministration of 5 -bromo -vinyl -uracil ( 5BVU ), a DPD inhibitor 5BVU, at a concentration of 25 M ( a nontoxic dose ), was incubated together with various concentrations of 5 -FU and cells were incubated at 378C for 4 hours. Cells were washed after incubation and medium was changed and incubated for 5 days. Percent cell survival of SFG -DPD -IRES -Neotransduced cells, 5BVU -treated transduced cells, and control cells was measured.
Northern blotting
Total cellular RNA was prepared according to the manufacturer's instructions using the Ultraspec RNA extraction reagent (Biotecx, Houston, TX ). Ten micrograms of RNA per sample was electrophoresed in agarose gels with MOPS buffer and then transferred to nitrocellulose filters, dried, UV-crosslinked, and hybridized to 32 P -labeled human DPD or 36B4 acidic ribosomal phosphoprotein probes and message expression was detected by autoradiography. 31 
DPD enzyme assay
NIH3T3 cells were harvested at 90-100% confluency and washed with cold buffer ( buffer A ) containing 35 mM potassium phosphate (pH 7.4), 2.5 mM magnesium chloride, and 10 mM 2-mercaptoethanol. The cells were removed by scraping and resuspended with cold buffer A, spun down to obtain pellets, and the pellets immediately frozen in dry ice and stored at À 708C. After thawing, cytosol was prepared and 200 g of protein was used for DPD enzyme assay, performed according to the method described by Johnson et al, 32 using [6 -14 C ] Fura (56 mCi / mmol ), NADH, and cytosolic protein. HPLC analysis was used to measure metabolites that included dihydrofluorouracil at different time points. Protein concentration was determined by the Bradford method. The specific activity is expressed as nanomoles of product per minute per milligram of protein.
Western blotting
One hundred micrograms of protein extract from NIH3T3 cells was processed for Western blot analysis using a 4 -20% gradient SDS -PAGE gel. After electrophoresis, the proteins were transferred to nitrocellulose filters following the method of Towbin et al. 33 The filter was incubated overnight at 48C with human DPD polyclonal antibody. 12 The filter was washed with borate -saline containing 0.1% Tween 20 ( v/ v) and incubated with a secondary, alkaline phosphatase -labeled, goat antirabbit antibody. Immunoreactive proteins were detected using a 0.1 -M sodium carbonate buffer, 100 mL (pH 9.5 ), containing 30 mg of nitro blue tetrazolium and 15 mg of 5 -bromo-4 -chloro-3-indolyl phosphate p-toluidine salt. A human peripheral mononuclear cell lysate was used as a positive control.
Mouse bone marrow transduction and CFU -GM assays CBA / DB2F1 male mice were treated with a single intravenous dose of 5-FU ( 150 mg /kg ). Four days later, bone marrow cells were harvested from both femurs and tibias, and resuspended in IMDM with 20% FBS and 10% WEHI -3B conditioned medium. Retroviral infection was carried out by the coculture method. In brief, bone marrow cells in IMDM containing 20% FBS were pipetted into 100 -mm plates, which contained approximately 80% confluent viral producer cells, irradiated at 1500 cGy on the day of coculture. The target -to -producer cell ratio was approximately 1:1. After 48 hours at 378C, nonadherent cells were harvested, washed with IMDM, and counted. 3Â10 4 cells were added to 10Â35 mm plates conditioning 2 mL of semisolid medium containing 1% methylcellulose, 20% FBS, 10% WEHI -3B conditioning medium, 1% Napyruvate, 1 M 2 -mercaptoethanol, 100 U /mL penicillin, 100 g /mL streptomycin, 1% essential amino acids, 1.5% nonessential amino acids, and 0.5% vitamin C. The cells were incubated with and without variable doses of 5-FU at 378C in 5% CO 2 . Colonies of more than 50 cells were scored after 10 days.
Human CD34 + -enriched cell transduction and CFU -GM assay
A CD34
+ -enriched population of cells from a healthy donor undergoing G -CSF mobilized leukapheresis was obtained using the Ceprate SC stem cell concentrator (CellPro, Bothell, WA ). CD34 + -enriched cells were stimulated into cycle with recombinant human stem cell factor ( rhSCF ) 20 ng /mL ( Kirin Pharmaceuticals, Tokyo, Japan ), recombinant human thrombopoietin ( rhTPO ) 100 ng/ mL (Kirin Pharmaceuticals ), rhFLT3 -L 100 ng/mL (Immunex, Seattle, WA ), recombinant human interleukin 6 (rhIL -6 ) 10 ng /mL ( Sigma, St. Louis, MO ), recombinant human granulocyte -macrophage colony -stimulating factor (rhGM-CSF ) 10 ng /mL (Sigma), and recombinant human granulocyte colony -stimulating factor ( rhG -CSF ) 100 ng /mL ( Amgen, Thousand Oaks, CA ). After 2 days of stimulation at 378C in a 5% CO 2 incubator, cells were cocultured with AM12-SFG -DPD -IRES -Neo producer cell line or mock as described above. In brief, AM12 producer cells were plated onto a 60 -mm dish (1Â10 6 cells /dish ) the day before and irradiated at 1500 cGy the following day. Prestimulated hematopoietic cells were collected, added onto each dish ( 1Â10 6 cells /dish ), and incubated for another 2 days in the presence of cytokines described above. CD34 + -enriched transduced cells were harvested, counted, and plated on 10Â35 mm culture dishes containing 1.5 mL of semisolid medium comprised of 1% methylcellulose, 30% FBS, 20 ng/ mL rhSCF, 20 ng /mL rhIL -6, 50 ng/ mL rhIL -3, 10 ng /mL rhG -CSF, 100 ng/ mL rhGM-CSF, 1 M 2 -mercaptoethanol, 100 U /mL penicillin, 100 mg /mL streptomycin, and 1% L -glutamine. The cells were incubated without and with variable doses of 5-FU either 4 hours or 14 ays at 378C in 5% CO 2 . Colonies of more than 50 cells were scored after 14 days.
Detection of proviral DNA in CFU -GM colonies by PCR amplification After 14 days of methylcellulose culture, CFU -GM colonies were analyzed by PCR. To estimate viral transduction efficiency, 10 colonies transduced by human DPD without 5 -FU treatment and 10 mock -transduced colonies were harvested, transferred into 0.5 -L Eppendorf tubes ( one tube for each colony ), resuspended in PBS, and washed twice. The pellet was resuspended with Higuchi's buffer 34 with proteinase K, incubated at 558C for 3 hours, followed by inactivation of proteinase K by heating at 958C for 10 minutes. For PCR, DPD primers (forward, DPD1; and reverse, DPD2; sequences described as above ) were used for transgene detection.
PCR conditions were 958C for 1 minute, 608C for 1 minute, and 728C for 2 minutes for 40 cycles. Five microliters of genomic DNA was used in a total volume of 50 L. Colonies transduced with SFG -DPD -IRES -Neo and mock were evaluated by PCR amplification of a 610-bp DPD cDNA fragment from genomic DNA using the primers described above.
The PCR products were analyzed by agarose gel electrophoresis and visualized by ethidium bromide staining.
Statistical analysis
Statistical comparisons were performed by the logistic regression model for the mouse bone marrow CFU -GM assay and by the Poisson regression model for the human CD34 + -enriched cell CFU -GM assay.
RESULTS
Human DPD and Neo gene transduction and expression in NIH3T3 cells
NIH3T3 cells were transduced with the supernatants of retrovirus -producing GP -envAM12 clones. The transduced NIH3T3 cells were generated by a single infection of viral supernatant followed by 10 -day selection with G418 ( 750 g/ mL ) containing media. Surviving colonies were harvested, pooled, and replated for subsequent experiments. The integration of transduced cDNA into the genome of NIH3T3 cells was detected by PCR (lanes 2 and 3, Fig 2) . Using primers specific for human DPD, a 610-bp DPD fragment was amplified from genomic DNA isolated from cells transduced with SFG -DPD -IRES -Neo. The genomic DNA from mock -transduced NIH3T3 cells showed no DPD amplification (lane 1, Fig 2 ) .
Human DPD mRNA expression in transduced NIH3T3 cells was detected using a human DPD cDNA probe. A major band at 6.4 kb and a minor band at 7.3 kb for spliced and unspliced mRNA, respectively, were detected ( Fig 3 ) . No DPD expression from mock -transduced cells was observed.
To show human DPD protein expression in transduced cells, cell lysates from transduced NIH3T3 cells and mock -transduced cells were analyzed by Western blotting using a polyclonal antibody to human DPD ( Fig 4 ) . Normal human mononuclear cells were used as positive control, as previously described. 13 Mock -transduced NIH3T3 cells showed a band at the corresponding level of DPD ( 110 kDa ). This was due to the nonspecific background staining of human DPD antibody to the mouse DPD ( Johnson et al, unpublished data ) and was less intense than the positive control band. The DPD band at 110 kDa in lysates from AM12 -SFG -DPD -IRES -Neotransduced cells (lane 3) was 10 -fold more intense than that seen in the lysates from normal peripheral blood mononuclear cells ( lane 1 used as a positive control; DPD band intensity was calculated after subtraction of background intensity observed in mock -transduced NIH3T3 cells) ( lane 2, Fig 4 ) .
Assay of DPD activity
DPD activity in NIH3T3 cells transduced with AM12-SFG -DPD -IRES -Neo vector was detected at the level of 0.02 nmol /min / mg. No enzyme activity ( < 0.001 nmol / min / mg ) was detected in untransduced NIH3T3 cells. The Western blot analysis for DPD tends to be more sensitive than the DPD enzyme assay, which is often unstable ( Johnson et al, unpublished data ).
Protection of virally transduced NIH3T3 cells from 5 -FU toxicity
To test whether the increased expression of human DPD observed was associated with increased 5 -FU resistance, AM12-SFG -DPD -IRES -Neo and mock -transduced (Fig 5) . This result was reproduced in three different experiments. In contrast, no significant protective effect from 5-FU was seen after 5 days of continuous exposure to this drug ( data not shown ). To further demonstrate that the 2 -fold increase in resistance to 5 -FU in transduced cells was due to increased expression of DPD enzyme activity, cells were treated with 25 M 5BVU, a DPD inhibitor that at this concentration has no cytotoxic effect alone, together with 5 -FU for 4 hours. Cytotoxicity of 5 -FU was increased to the level of the control cell line ( Fig 5 ) .
Transduction of AM12 -SFG -DPD -IRES-Neo into mouse bone marrow cells
As the studies with NIH3T3 cells gave encouraging results, the retroviral vector containing human DPD was used to ascertain whether successful transduction and expression of DPD protect mouse bone marrow progenitor cells from 5-FU toxicity. Mouse bone marrow cells, either mock -infected or infected with supernatant from the AM12 -SFG -DPD -IRES -Neo viral producer cell line, were exposed to various doses of 5 -FU for 4 hours or 10 days and were analyzed for CFU -GM colony formation in semisolid medium (Table 1a and b). For G -418 colonies, mock -transduced bone marrow cells did not show any colonies at 800 g /mL G -418, whereas 24% of DPD -I -Neo -transduced colonies grew at this dose ( Table 1c) . Transduction of human DPD resulted in an increased number of 5-FU -resistant CFU -GM colonies at both the 4 -hour and 10 -day drug exposures. For example, at 10 À 6 M 5-FU for a 10-day exposure, 46% colonies was seen in the mock -transduced group, whereas 85% was observed in the SFG -DPD -IRES -Neo -transduced group. In the 4 -hour 5-FU exposure group ( 10 À 5 M), there were only two colonies ( 2% ) seen in the mock -transduced group, whereas 46 colonies ( 18% ) were seen for SFG -DPD -IRES -Neo -transduced group.
Transduction of human CD34
+ -enriched hematopoietic progenitor cells with AM12 -SFG -DPD -IRES -Neo
Transduced human CD34
+ -enriched cells with AM12-SFG -DPD -IRES -Neo and mock -infected cells were exposed to 5 -FU at 10 À 6 M or 10 À 7 M for 14 days. At 10 À 7 M concentration of 5 -FU, there was an increased number of colonies resistant to 5 -FU in the AM12-SFG -DPD -IRES -Neo -infected cells (38% of control ) compared to the mock -infected cells ( 9% of control ). At 10 À 6 M 5 -FU, there were no surviving colonies in the mocktransduced group, whereas in the DPD -transduced group, 39 colonies survived (18% of control ) (Table 2a ). In the 4 -hour 5 -FU exposure experiment, a higher concentration of 5 -FU (10 À 5 M ) resulted in a colony survival difference between DPD and mock -transduced cells (65% vs 12%, P <.05) ( Table 2b ). At 800 g/ mL G -418, less than 1% of mocktransduced cells survived, whereas 22% of the DPD -I -Neotransduced cells grew as colonies at this dose (Table 2c ) .
Detection of proviral integration into human progenitor cells by PCR. In order to estimate the transduction efficiency of this viral construct, genomic DNA was isolated from human progenitor cell CFU -GM colonies after infection with AM12-SFG -DPD -IRES -Neo without drug exposure for PCR amplification of the DPD cDNA fragment. Detection of the 610 -bp DPD cDNA product was observed in seven individual colonies out of 10 randomly selected coloniesapproximately a 70% transduction efficiency. P values were less than .01 for all mean comparisons between AM12 mock and DPD -I -Neo; t test used. P value less than .01 for all mean comparisons between AM12 mock and DPD -I -Neo, using t test.
Cancer Gene Therapy, No amplification product was seen in mock -transduced colonies (Fig 6 ) . PCR amplification of pooled CFU -GM colonies (ca. five colonies) using Neo sequence detecting primers were performed as well. The SFG -DPD -IRESNeo -transduced colonies with and without 5 -FU exposure were positive for Neo cDNA, but not detected from mocktransduced colonies (data not shown ).
DISCUSSION
We exposed transduced NIH3T3 cells to 5 -FU for 4 hours, simulating the AUC ( area under the plasma concentration versus time curve ) produced by a bolus infusion used in the clinic, as well as for 5 days, simulating the continuous infusion schedule. 35 Of interest, more protection was demonstrated against 5 -FU toxicity after a 4 -hour exposure compared to the continuous exposure. An irreversible DPD inhibitor, 5BVU (used at nontoxic doses ), reversed 5 -FU resistance in the transduced cells to the level of control cells, confirming that forced expression of DPD was associated with the increased 5 -FU resistance observed.
Transduction of mouse hematopoietic progenitors resulted in increased numbers of 5 -FU -resistant CFU -GM colonies, both with 4 -hour and 10 -to 14 -day 5-FU exposures. Human CD34 + -enriched progenitors transduced with DPD cDNA showed modest 5-FU resistance (14 -day exposure ). DPD and Neo gene integration into DNA was detected by PCR in human CFU -GM colonies.
Genes conferring 5 -FU resistance to 5-FU in hematopoietic progenitor cells may have a potential advantage for in vivo selection. For example, Molineux et al 23 showed that prior exposure to stem cell factor ( SCF ) markedly enhanced 5 -FU -mediated progenitor toxicity. If a gene conferring 5-FU resistance was present in a small proportion of progenitor cells, a single cycle of SCF prestimulation and 5-FU administration could increase the percentage of transduced drug -resistant progenitor cells. These results point to the potential application of 5 -FU drug resistance gene transfer preceded by cytokine prestimulation as an in vivo selection strategy.
The use of a 5 -FU drug resistance gene to select genetically modified hematopoietic stem cells in vivo was also suggested by Blau et al. 36 Multiple administrations of 5 -FU eradicated mouse stem cell populations. 24 This effect occurred without the presence of nucleoside transport inhibitors, which were required to sensitize repopulating hematopoietic stem cells to antifolates. 24 Thus, 5 -FU toxicity to hematopoietic stem cells and myeloid progenitors is not protected by the thymidine salvage mechanism, which suggests that hematopoietic toxicity of high pulse doses of 5-FU may not be mediated primarily by inhibition of thymidylate synthase (TS ), but likely through inhibition of RNA synthesis, 35 possibly reversed more effectively by overexpression of DPD enzyme activity as shown in the NIH3T3 experiments. Transduction of human progenitor cells by DPD cDNA may thus not only protect bone marrow from high -dose 5-FU treatment, but may also be a useful strategy for the in vivo selection of genetically modified hematopoietic stem cells. Figure 6 . Detection of proviral integration into human progenitor cells by PCR. DNA was isolated from individual CFU -GM colonies derived from CD34 + progenitor cells, and PCR amplification using primers for DPD carried out as described in Materials and Methods. Lanes 1 -10 show human DPD cDNA detected from human CD34 + progenitor cell CFU -GM genomic DNA after transduction with AM12 -SFG -DPD -IRES -Neo without drug exposure ( see Materials and Methods ). Lanes 1, 2, 4, 7, 8, 9, and 10 show a band detected at 610 bp. Lane 11 is PCR -amplified genomic DNA from a mock -transduced CFU -GM colony using DPD primers. Lanes 12 and 13 show PCR amplification of genomic DNA from the AM12 -SFG -DPD -IRES -Neo producer cell line and plasmid cDNA ( SFG -DPD -IRES -Neo ) using DPD primers ( positive controls ). Samples were run with a molecular weight marker ( $X ).
